Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:18711188rdf:typepubmed:Citationlld:pubmed
pubmed-article:18711188lifeskim:mentionsumls-concept:C0013216lld:lifeskim
pubmed-article:18711188lifeskim:mentionsumls-concept:C0684249lld:lifeskim
pubmed-article:18711188lifeskim:mentionsumls-concept:C0034656lld:lifeskim
pubmed-article:18711188lifeskim:mentionsumls-concept:C0243192lld:lifeskim
pubmed-article:18711188lifeskim:mentionsumls-concept:C0032207lld:lifeskim
pubmed-article:18711188lifeskim:mentionsumls-concept:C0963057lld:lifeskim
pubmed-article:18711188lifeskim:mentionsumls-concept:C0282460lld:lifeskim
pubmed-article:18711188lifeskim:mentionsumls-concept:C0205195lld:lifeskim
pubmed-article:18711188lifeskim:mentionsumls-concept:C0215136lld:lifeskim
pubmed-article:18711188lifeskim:mentionsumls-concept:C2000258lld:lifeskim
pubmed-article:18711188pubmed:issue24lld:pubmed
pubmed-article:18711188pubmed:dateCreated2008-8-19lld:pubmed
pubmed-article:18711188pubmed:abstractTextThis study assessed the efficacy of the combination of standard taxane plus platinum chemotherapy with the synthetic Toll-like receptor 9-activating oligodeoxynucleotide PF-3512676 in patients with non-small-cell lung cancer (NSCLC).lld:pubmed
pubmed-article:18711188pubmed:languageenglld:pubmed
pubmed-article:18711188pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18711188pubmed:citationSubsetIMlld:pubmed
pubmed-article:18711188pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18711188pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18711188pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18711188pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18711188pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18711188pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18711188pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18711188pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18711188pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:18711188pubmed:statusMEDLINElld:pubmed
pubmed-article:18711188pubmed:monthAuglld:pubmed
pubmed-article:18711188pubmed:issn1527-7755lld:pubmed
pubmed-article:18711188pubmed:authorpubmed-author:KriegArthur...lld:pubmed
pubmed-article:18711188pubmed:authorpubmed-author:ManegoldChris...lld:pubmed
pubmed-article:18711188pubmed:authorpubmed-author:LeichmanCynth...lld:pubmed
pubmed-article:18711188pubmed:authorpubmed-author:HirshVeraVlld:pubmed
pubmed-article:18711188pubmed:authorpubmed-author:MezgerJörgJlld:pubmed
pubmed-article:18711188pubmed:authorpubmed-author:Al-AdhamiMoha...lld:pubmed
pubmed-article:18711188pubmed:authorpubmed-author:GravenorDonal...lld:pubmed
pubmed-article:18711188pubmed:authorpubmed-author:WoytowitzDona...lld:pubmed
pubmed-article:18711188pubmed:authorpubmed-author:AlbertGaryGlld:pubmed
pubmed-article:18711188pubmed:authorpubmed-author:ReadettDavidDlld:pubmed
pubmed-article:18711188pubmed:issnTypeElectroniclld:pubmed
pubmed-article:18711188pubmed:day20lld:pubmed
pubmed-article:18711188pubmed:volume26lld:pubmed
pubmed-article:18711188pubmed:ownerNLMlld:pubmed
pubmed-article:18711188pubmed:authorsCompleteYlld:pubmed
pubmed-article:18711188pubmed:pagination3979-86lld:pubmed
pubmed-article:18711188pubmed:meshHeadingpubmed-meshheading:18711188...lld:pubmed
pubmed-article:18711188pubmed:meshHeadingpubmed-meshheading:18711188...lld:pubmed
pubmed-article:18711188pubmed:meshHeadingpubmed-meshheading:18711188...lld:pubmed
pubmed-article:18711188pubmed:meshHeadingpubmed-meshheading:18711188...lld:pubmed
pubmed-article:18711188pubmed:meshHeadingpubmed-meshheading:18711188...lld:pubmed
pubmed-article:18711188pubmed:meshHeadingpubmed-meshheading:18711188...lld:pubmed
pubmed-article:18711188pubmed:meshHeadingpubmed-meshheading:18711188...lld:pubmed
pubmed-article:18711188pubmed:meshHeadingpubmed-meshheading:18711188...lld:pubmed
pubmed-article:18711188pubmed:meshHeadingpubmed-meshheading:18711188...lld:pubmed
pubmed-article:18711188pubmed:meshHeadingpubmed-meshheading:18711188...lld:pubmed
pubmed-article:18711188pubmed:meshHeadingpubmed-meshheading:18711188...lld:pubmed
pubmed-article:18711188pubmed:meshHeadingpubmed-meshheading:18711188...lld:pubmed
pubmed-article:18711188pubmed:meshHeadingpubmed-meshheading:18711188...lld:pubmed
pubmed-article:18711188pubmed:meshHeadingpubmed-meshheading:18711188...lld:pubmed
pubmed-article:18711188pubmed:meshHeadingpubmed-meshheading:18711188...lld:pubmed
pubmed-article:18711188pubmed:year2008lld:pubmed
pubmed-article:18711188pubmed:articleTitleRandomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer.lld:pubmed
pubmed-article:18711188pubmed:affiliationUniversity Medical Center Mannheim, Heidelberg University, Mannheim, Germany. Prof.Manegold@t-online.delld:pubmed
pubmed-article:18711188pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:18711188pubmed:publicationTypeComparative Studylld:pubmed
pubmed-article:18711188pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:18711188pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:18711188pubmed:publicationTypeMulticenter Studylld:pubmed
pubmed-article:18711188pubmed:publicationTypeClinical Trial, Phase IIlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18711188lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18711188lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18711188lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:18711188lld:pubmed